Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "metastatic" Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Adacel® Vaccine Administered to Persons 10 Years of Age

NCT01311557
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed
Biological
Lead sponsor
Sanofi
Industry
Eligibility
10 Years to 11 Years
Enrollment
1,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
34
States / cities
Chandler, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Jul 24, 2026, 2:05 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

NCT02224781
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Ipilimumab, Multigated Acquisition Scan, Nivolumab, Quality-of-Life Assessment, Trametinib Dimethyl Sulfoxide
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
839
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 529 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy

NCT01665911
View directory record Official record
Conditions
Caries
Interventions
1.5 mg Sodium Fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk, Non-fluoridated milk, 200 ml
Drug · Other
Lead sponsor
Frank Lippert
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Jul 24, 2026, 2:05 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain

NCT01189071
View directory record Official record
Conditions
Overactive Bladder, Renal Colic, Pain, Postoperative
Interventions
Darifenacin
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Jul 24, 2026, 2:05 AM EDT
Enrolling by invitation Phase 3 Interventional

An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

NCT07424144
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Itepekimab (SAR440340), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
La Mesa, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Mental Health Improvements After Using Home Phototherapy Device With UVB LEDs

NCT05235334
View directory record Official record
Conditions
Usability, Quality of Life
Interventions
MySOLIUS
Device
Lead sponsor
BeneSol, Inc. dba SOLIUS
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Jul 24, 2026, 2:05 AM EDT
Recruiting Phase 2 Interventional

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

NCT04363164
View directory record Official record
Conditions
Castration Resistant Metastatic Prostate Cancer
Interventions
Testosterone cypionate, Enzalutamide, Testosterone enanthate
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
6
States / cities
San Diego, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

Open-Label, Extension Study to 810P202

NCT01416064
View directory record Official record
Conditions
Impulsive Aggression Comorbid With ADHD in Children
Interventions
Molindone
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Dothan, Alabama • Los Angeles, California • Santa Ana, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Jul 24, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional Results available

Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar

NCT00475332
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Follicular Lymphoma
Interventions
Iodine I -01 Tositumomab (Bexxar), External Beam Radiation Therapy
Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Not applicable Interventional

TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine

NCT00023387
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifapentine, 25-desacetyl Rifapentine, Isoniazid
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2005 · Synced Jul 24, 2026, 2:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Parkinsonism in Spinocerebellar Ataxia Type 6

NCT01934998
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 6
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Jul 24, 2026, 2:05 AM EDT
Recruiting Phase 2 Interventional

Bumetanide in Patients With Alzheimer's Disease

NCT06052163
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Bumetanide, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jul 24, 2026, 2:05 AM EDT
Terminated Phase 1 Interventional

Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)

NCT04046887
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Lonsurf, Gemcitabine, Nab-Paclitaxel
Drug
Lead sponsor
Patrick Joseph Loehrer Sr.
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jul 24, 2026, 2:05 AM EDT
Withdrawn Phase 2 Interventional

Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy

NCT00982787
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Botanical extract from Passiflora incarnata
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

N-acetylcysteine in Alcohol Dependence

NCT00568087
View directory record Official record
Conditions
Alcoholism
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Jul 24, 2026, 2:05 AM EDT
Active, not recruiting Phase 3 Interventional

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

NCT04136353
View directory record Official record
Conditions
Prostate Cancer
Interventions
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
Drug · Radiation
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
19
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Burlington, Massachusetts + 15 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 24, 2026, 2:05 AM EDT
Terminated Phase 1 Interventional

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

NCT06560645
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma
Interventions
PRT7732
Drug
Lead sponsor
Prelude Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
San Francisco, California • Detroit, Michigan • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Not applicable Interventional

Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer

NCT01655745
View directory record Official record
Conditions
Bladder Cancer
Interventions
FDG PET/MR
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Jul 24, 2026, 2:05 AM EDT
Completed No phase listed Observational

A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis

NCT05334472
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Kesimpta
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

NCT03571672
View directory record Official record
Conditions
Cardiac Disease
Interventions
DEFINITY
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Tucson, Arizona • San Diego, California • Wilmington, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass

NCT02151877
View directory record Official record
Conditions
Ischemia/Reperfusion Injury After Neonatal Cardiac Surgery, Inflammatory Reaction After Neonatal Cardiac Surgery
Interventions
Inhaled Nitric Oxide, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
1 Day to 30 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jul 24, 2026, 2:05 AM EDT
Recruiting Not applicable Interventional

Telephone Support in Advanced Gastrointestinal Cancer

NCT06532877
View directory record Official record
Conditions
Gastrointestinal Neoplasm Malignant, Caregiver Burden
Interventions
Acceptance and Commitment Therapy, Education/Support
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Chicago, Illinois • Indianapolis, Indiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00571675
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
AT-101, prednisone and docetaxel, placebo, prednisone and docetaxel
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Colorado Springs, Colorado • New Port Richey, Florida • Ocoee, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2010 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Not applicable Interventional Results available

Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

NCT00303901
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
cryosurgery, positron emission tomography
Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Jul 24, 2026, 2:05 AM EDT